Draft:Ipilimumab induced hypophysitis

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

Retrieved on: 
Tuesday, October 27, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Drugs, Clinical medicine, Cancer treatments, Bristol-Myers Squibb, Antineoplastic drugs, Breakthrough therapy, Nivolumab, Ipilimumab, Renal cell carcinoma, Melanoma, Draft:Ipilimumab induced hypophysitis, Pembrolizumab, CheckMate -9ER, RCC, CABOMETYX® (cabozantinib)

OPDIVO (nivolumab), as a single agent, is indicated for the treatment of patients with unresectable or metastatic melanoma.

Key Points: 
  • OPDIVO (nivolumab), as a single agent, is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • OPDIVO (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
  • OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

Retrieved on: 
Saturday, September 19, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Bristol-Myers Squibb, Clinical medicine, Medicine, Antineoplastic drugs, Breakthrough therapy, RTT, Nivolumab, Ipilimumab, Renal cell carcinoma, Draft:Ipilimumab induced hypophysitis

CheckMate -9ER is an open-label, randomized, multi-national Phase 3 trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

Key Points: 
  • CheckMate -9ER is an open-label, randomized, multi-national Phase 3 trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).
  • OPDIVO (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
  • OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).
  • In MSI-H/dMMR mCRC patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated pneumonitis occurred in 1.7% (2/119) of patients.